Business Context and Reporting Period
This Form 8-K was filed by Xcyte Therapies, Inc. (not Bio Green Med Solution, Inc.) on February 7, 2006. The report addresses a critical corporate event regarding the company's listing status on The Nasdaq National Market following a period of non-compliance with minimum bid price requirements.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on regulatory compliance and listing status.
Material Changes
The primary material change is the resolution of a delisting threat. After failing to regain compliance with Nasdaq's $1.00 minimum bid price rule by the December 5, 2005 deadline, the company appealed the decision. On February 7, 2006, the Nasdaq Listing Qualifications Panel granted Xcyte's request for continued listing, reversing the prior determination of delisting.
Guidance, Outlook, and Conditions
The continued listing is subject to strict conditions imposed by the Nasdaq Listing Qualifications Panel:
- Xcyte must announce the consummation of the acquisition of Cyclacel Limited.
- Xcyte must file a new listing application with Nasdaq pursuant to "reverse merger" rules.
- The new listing application must be filed on or before April 12, 2006.
Management commentary is limited to the procedural history of the appeal and the specific terms of the panel's decision.
Investor Verification Checklist
- Verify the status of the acquisition of Cyclacel Limited.
- Confirm whether Xcyte has filed the required new listing application under reverse merger rules by the April 12, 2006 deadline.
- Monitor the company's stock bid price to ensure it meets the $1.00 minimum requirement to avoid future delisting notices.
- Review subsequent filings for any updates on the Nasdaq approval of the new listing application.